Skip to main content
ConductScienceScienceDex

Michael G Agadjanyan

NIH Rank #475
Unclaimed recordClaim profile
  • Program Leader
  • Top 5% Funded
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 1870529Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

NIH Funding · FY2025

Linked Award Amount
$9.4M
Full award amounts, FY2025
Award Records
3
Records listing this PI
Award-Linked Rank
#475
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Michael G Agadjanyan. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2025 award records by amount

NIH award records listing Michael G Agadjanyan as a PI. Multi-PI records show the full award amount for context.

  • 1R01AG092949-01R01
    FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.
    Institute for Molecular Medicine
    $5.3M
    award amount
  • 5R01AG074983-04R01
    Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
    Institute for Molecular Medicine
    $2.3M
    award amount
  • 5U01AG084528-02U01
    IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
    Institute for Molecular Medicine
    $1.8M
    award amount

Award organization

Organizations that administered FY2025 awards listing Michael G Agadjanyan as a PI.

FY2025 award administered by Institute for Molecular Medicine (CA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Institute for Molecular Medicine
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #1604
  6. 2024
    Entered Top 25% Nationally
    Ranked #1604
  7. 2024
    Entered Top 10% Nationally
    Ranked #1604
  8. 2025
    $5M Cumulative Funding
  9. 2025
    $10M Cumulative Funding
  10. 2025
    Entered Top 5% Nationally
    Ranked #475
  11. 2025
    R01 Grant Holder
  12. 2025
    Program/Center Grant Leader

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Michael G Agadjanyan.

Lon S Schneider
Institute for Molecular Medicine
4
shared awards
David Sultzer
Institute for Molecular Medicine
3
shared awards
James E Galvin
Institute for Molecular Medicine
3
shared awards
Duygu Tosun-turgut
Institute for Molecular Medicine
1
shared award

Explore further

Find collaborators for Michael G Agadjanyan

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →